National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups - Full Text View

National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups (COMPAR)

This study is currently recruiting participants.
Verified by AstraZeneca, June 2008

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00699959

Purpose

The purpose of this observational study is to compare frequency of attainment control goals through the more represented cardiovascular factor risk, dyslipidemia, among coronary patients with or without heart failure in cardiology consulting.

Condition

Coronary Patients
Heart Failure

MedlinePlus related topics:

Heart Failure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Cross-Sectional

Official Title:	Comparison and Description of Coronary Patients Management With or Without Heart Failure in Cardiology Consulting

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Frequency of attainment control goals through the more represented cardiovascular factor risk, dyslipidemia, among coronary patients with or without heart failure in cardiology consulting. [ Time Frame: Once ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	2000
Study Start Date:	June 2008
Estimated Study Completion Date:	September 2008

Groups/Cohorts

patients with heart failure

patients without heart failure

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

First two consecutive Coronary patients with or without heart failure

Criteria

Inclusion Criteria:

patient with coronary disease diagnosed since at least 1 year
Echocardiography done less than 1 year ago
patient with or without documented heart failure

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00699959

Contacts


Contact: AstraZeneca Clinical Study Information	01 41 29 40 00	stephan.becouarn@astrazeneca.com

Show 343 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	Alain Castaigne	AstraZeneca

More Information

Responsible Party:	AstraZeneca Pharmaceuticals ( Alain Castaigne, Medical Director )
Study ID Numbers:	NIS-CFR-DUM-2007/8
First Received:	June 16, 2008
Last Updated:	June 17, 2008
ClinicalTrials.gov Identifier:	NCT00699959
Health Authority:	France: French Data Protection Authority

Keywords provided by AstraZeneca:

Coronary patients

heart failure

dyslipidemia

Study placed in the following topic categories:

Heart Failure

Heart Diseases

Dyslipidemias

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 10, 2008